Hedgehog inhibitors for basal cell carcinoma cause significant side effects like dysgeusia and muscle cramps. To improve tolerability and long-term adherence, clinicians use practical strategies like scheduled treatment interruptions (e.g., weeks on, weeks off) rather than continuous daily dosing.

The new nilotinib formulation is unaffected by food, preventing dangerous spikes in drug concentration. This stability may reduce the risk of arterial occlusive events, a major concern with the original drug, which could have been triggered by patients eating too close to their dose.

A critical reason patients stop ADC treatments is the burden of side effects like skin toxicity or GI issues, not just disease progression. This underscores the urgent need to develop ADCs with better safety profiles, enabling patients to stay on effective therapy longer.

Despite proven benefits, side effects from adjuvant CDK4/6 inhibitors like abemaciclib create significant adherence challenges. The speaker notes that in practice, almost no patient completes the full multi-year course at the starting dose. Even in a supportive study, 20% of patients discontinued therapy within six months, highlighting a critical gap between trial efficacy and real-world tolerability.

Despite showing massive weight loss, new obesity drugs from Eli Lilly and others have high discontinuation rates due to side effects. This suggests the industry's singular focus on efficacy may be hitting diminishing returns, opening a new competitive front based on better patient tolerance and adherence.

Long-term CML therapy success hinges on adherence. Minor intolerances and lifestyle inconveniences, which accumulate over a lifetime of treatment, are more likely to cause patients to stop therapy than the drug failing to work, compromising outcomes.

The LIDERA trial showed that while jiridestrant and standard therapies had similar adverse event profiles, patients on jiridestrant had significantly lower discontinuation rates. This highlights that a patient's subjective experience of tolerability is a more critical factor for long-term adherence than a simple list of side effects.

Despite being a pill, oral Wegovy requires an empty stomach, only 4oz of water, and a 30-minute post-dose fast. This difficult regimen is a major impediment to its uptake, particularly in the U.S. where patients prioritize the maximum efficacy of injectables over the supposed convenience of a cumbersome pill.

Alternate TKI formulations, like nilotinib, are engineered to be superior to parent compounds. They remove dietary restrictions (fasting) and interference from acid reducers, ensuring consistent drug exposure. This can reduce adverse effects and improve patient quality of life, moving beyond the simple 'biosimilar' label.